Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $593,000 | reported | |
| FY 2024 | 2024-12-31 | $683,000 | reported | |
| FY 2023 | 2023-12-31 | $488,000 | reported | |
| FY 2022 | 2022-12-31 | $386,000 | reported | |
| FY 2021 | 2021-12-31 | $359,000 | reported | |
| FY 2020 | 2020-12-31 | $366,000 | reported | |
| FY 2019 | 2019-12-31 | $244,632 | reported | |
| FY 2018 | 2018-12-31 | $378,325 | reported | |
| FY 2017 | 2017-12-31 | $505,404 | reported | |
| FY 2016 | 2016-12-31 | $381,072 | reported | |
| FY 2015 | 2015-12-31 | $312,812 | reported | |
| FY 2014 | 2014-12-31 | $280,178 | reported |
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Twelve months to Sep 30, 2026 · derived
Cardiff Oncology, Inc. is the 82nd largest of the 177 covered companies the SEC files under this code, by revenue. SIC 2836
Latest filing Nov 16, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
74 managers · Quarter ended Sep 30, 2026All holders ›
2